Apr 22 |
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript
|
Apr 18 |
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
|
Apr 16 |
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
|
Apr 9 |
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
|
Apr 3 |
YS Biopharma announces full repayment of $40M loan facility
|
Apr 3 |
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
|
Mar 5 |
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
|
Feb 22 |
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
|
Feb 18 |
/C O R R E C T I O N -- YS Biopharma Co., Ltd./
|
Feb 9 |
YS Biopharma announces $40M private placement
|